当前位置:首页>产品中心>单抗/多抗>Epcoritamab ELISA Kit|Epcoritamab ELISA试剂盒(靶标:)

Epcoritamab ELISA Kit|Epcoritamab ELISA试剂盒(靶标:)

  • 货号:RB9TDY257038
  • 价格:面议
  • 点击:306
   一键复制产品信息 复制成功!

产品介绍

产品参数

应用ELISA
检测方法Colorimetric
灵敏度0.156 μg/ml
检测范围0.31-5 μg/mL
回收率80-120%
样本类型Plasma, Serum
检测类型Quantitative
稳定性和储存The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
运输条件2-8 ℃
登录号P11836 & P07766
背景信息Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from newly diagnosed (ND) and relapsed/refractory (RR) B-NHL patients. In the presence of T-cells from a healthy donor, epcoritamab demonstrated potent activity against primary tumor cells, irrespective of prior treatments, including CD20 mAbs. Median lysis of 65, 74, and 84% were achieved in diffuse large B-cell lymphoma (n = 16), follicular lymphoma (n = 15), and mantle cell lymphoma (n = 8), respectively. Furthermore, in this allogeneic setting, we discovered that the capacity of B-cell tumors to activate T-cells was heterogeneous and showed an inverse association with their surface expression levels of the immune checkpoint molecule Herpesvirus Entry Mediator (HVEM). In the autologous setting, when lymph node (LN)-residing T-cells were the only source of effector cells, the epcoritamab-dependent cytotoxicity strongly correlated with local effector cell-to-target cell ratios. Further analyses revealed that LN-residing-derived or peripheral blood-derived T-cells of B-NHL patients, as well as heathy donor T-cells equally mediated epcoritamab-dependent cytotoxicity. These results show the promise of epcoritamab for treatment of newly-diagnosed or relapsed/refractory B-NHL patients, including those who became refractory to previous CD20-directed therapies.
别名GEN3013, 2134641-34-0
备注For Research Use Only.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Research Grade Lunaxafusp|研究级Lunaxafusp(靶标:Lunaxafusp(研究用)) 576
Anti-Mouse C5 Recombinant Antibody|抗小鼠C5重组抗体(靶标:小鼠补体C5) 469
Anti-Pembrolizumab Neutralizing Recombinant Antibody |抗帕博利珠单抗中和重组抗体(靶标:帕博利珠单抗中和抗体) 457
Anti-Pembrolizumab Neutralizing Recombinant Antibody |抗帕博利珠单抗中和重组抗体(靶标:帕博利珠单抗中和抗体) 275
Anti-Human CD39/ENTPD1 Recombinant Antibody|抗人CD39/ENTPD1重组抗体(靶标:人外核苷酸三磷酸二磷酸水解酶1/CD39) 326
Anti-Glycophorin A (type M) Recombinant Antibody|抗血型糖蛋白A(M型)重组抗体(靶标:人血型糖蛋白A(M型)) 648
Anti-Glycophorin A (type N) Recombinant Antibody|抗血型糖蛋白A(N型)重组抗体(靶标:人血型糖蛋白A(N型)) 315
Anti-Glycophorin A (type N) Recombinant Antibody|抗血型糖蛋白A(N型)重组抗体(靶标:人血型糖蛋白A(N型)) 578
Anti-Glycophorin A (type M) Recombinant Antibody|抗血型糖蛋白A(M型)重组抗体(靶标:人血型糖蛋白A(M型)) 364
Anti-Human α4β7/ITGA4 & ITGB7 Recombinant Antibody |抗人α4β7/ITGA4和ITGB7重组抗体(靶标:人整合素α4β7复合物) 322
Anti-Human CD2BP2 Polyclonal Antibody|抗人CD2BP2多克隆抗体(靶标:人CD2结合蛋白2) 513
InVivoMAb anti-Mouse IL-6R alpha&IL6R Antibody|InVivoMAb抗小鼠IL-6Rα和IL6R抗体(靶标:小鼠白细胞介素6受体) 565
Anti-Human EGFR/ERBB1/HER1 Reference Antibody|抗人EGFR/ERBB1/HER1参照抗体(靶标:人表皮生长因子受体(研究用)) 458
Anti-Human CD279/PD-1 Recombinant Antibody|抗人CD279/PD-1重组抗体(靶标:人程序性细胞死亡蛋白1/PD-1) 565
Anti-Human CD279/PD-1 Recombinant Antibody, FITC|抗人CD279/PD-1重组抗体, FITC标记(靶标:人程序性细胞死亡蛋白1/PD-1(FITC标记)) 565
Anti-Human CD279/PD-1 Recombinant Antibody, PE|抗人CD279/PD-1重组抗体, PE标记(靶标:人程序性细胞死亡蛋白1/PD-1(PE标记)) 462
Anti-Human CD279/PD-1 Recombinant Antibody, APC|抗人CD279/PD-1重组抗体, APC标记(靶标:人程序性细胞死亡蛋白1/PD-1(APC标记)) 685
Anti-Human CD279/PD-1 Recombinant Antibody, PerCP|抗人CD279/PD-1重组抗体, PerCP标记(靶标:人程序性细胞死亡蛋白1/PD-1(PerCP标记)) 551
Anti-Omalizumab Neutralizing Recombinant Antibody |抗奥马珠单抗中和重组抗体(靶标:奥马珠单抗中和抗体) 335
Anti-Omalizumab Neutralizing Recombinant Antibody |抗奥马珠单抗中和重组抗体(靶标:奥马珠单抗中和抗体) 279
总计 33037 个记录,共 1652 页,当前第 1643 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00